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In October 2011, the Advisory Committee on Immunization Practices (ACIP) first 
recommended the routine administration of a tetanus, diphtheria, and acellular pertussis 
vaccine (Tdap) during pregnancy as a strategy to protect infants from pertussis (also known 
as whooping cough) (1). This recommendation applied to women previously unvaccinated 
with Tdap and specified the optimal vaccination time as late second or third trimester (after 
20 weeks’ gestation) (1). By vaccinating pregnant women, infants, who are at highest risk 
for mortality and morbidity from pertussis, gain passive immunity from maternal antibodies 
transferred to them in utero (2-4). Since this recommendation was made, little has been 
published on the percentage of women receiving Tdap during pregnancy. In Michigan, 
Medicaid pays for costs of pregnancy for approximately 40% of births (5). Infants enrolled 
in Medicaid are a particularly vulnerable population; in Michigan, their all-cause mortality is 
higher than that of privately insured infants.* To assess vaccination coverage among 
pregnant women enrolled in a publicly funded insurance program in Michigan, Medicaid 
administrative claims data and statewide immunization information system data for mothers 
of infants born during November 2011–February 2013 were analyzed. This report describes 
the results of that analysis, which indicated that only 14.3% of these women received Tdap 
during pregnancy, with rates highest (17.6%) among non-Hispanic, non-Arab whites and 
lowest (6.8%) among Arab women.† Vaccination was related to maternal age and gestational 
age at birth, but not to adequacy of prenatal care. In 2013, recognizing the importance of 
Tdap for every pregnancy, ACIP revised its guidelines to include a Tdap dose during every 
pregnancy (6). Ensuring that all infants receive the protection against pertussis afforded by 
maternal vaccination will require enhanced efforts to vaccinate pregnant women.
Corresponding author: Michelle Housey, mhousey@med.umich.edu, 734-936-5334. 
*Michigan ranks second in the United States for largest Arab population. The Division for Vital Records and Health Statistics at the 
Michigan Department of Community Health collects Arab ethnicity on the birth certificate.†Information available at https://michigan.gov/documents/mdch/Infant_Mortality_Final_Deliverable_433533_7.pdf.
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Birth certificates for infants born during November 2011–February 2013 were linked to 
maternal Medicaid claims data. Only women who delivered their first infant at age ≥18 years 
and who received full Medicaid benefits for at least 1 month between 20 weeks gestation 
and live birth were included. Preterm and full-term infants (defined as those delivered at ≤42 
weeks’ gestation) were included. Pregnant adolescents were excluded because they should 
be vaccinated with Tdap based on their age (i.e., 11–18 years), independent of their 
pregnancy status. Using each infant’s birth date and gestational age at birth, an approximate 
date of conception was calculated. International Classification of Diseases, Ninth Revision 
(ICD-9) procedural codes for vaccination with Tdap (code 99.39) and the Current 
Procedural Terminology codes for vaccination with Tdap (code 90715) were used to identify 
vaccinations given any time during pregnancy. Statewide immunization information system 
data from the Michigan Care Improvement Registry supplemented Medicaid data to capture 
more complete vaccination histories during pregnancy.
The percentage of women who received a Tdap vaccination at any time during pregnancy 
and disparities in vaccination administration based on maternal race/ethnicity were 
evaluated. Maternal race/ethnicity was categorized as non-Hispanic and non-Arab white 
(“white”), non-Hispanic and non-Arab black (“black”), non-Hispanic and non-Arab Asian 
(“Asian”), non-Hispanic and non-Arab Native American (“Native American”), Hispanic, or 
Arab based on the birth certificate. Other potential predictors of vaccination were assessed 
including gestational age at live birth, plurality of the pregnancy, maternal age at live birth, 
and adequacy of prenatal care use using the Kotelchuck index (7). Relative risks assessed 
differences by maternal race and ethnicity adjusting for two significant predictors of 
vaccination, maternal age and gestational age at delivery. An alpha level of <0.05 denoted 
statistical significance.
A total of 15,181 women were included in the study (Table 1). The majority of women were 
white (59.3%), and the second largest racial/ethnic group was black (29.6%). Approximately 
65.5% of infants were born full-term (at ≥39 weeks), and the overwhelming majority of 
pregnancies were singleton (98.7%). Based on the Kotelchuck index, over half of the study 
population received either intermediate (37.6%) or inadequate (37.5%) prenatal care. The 
median maternal age at delivery for the entire study population was 21.0 years (Table 1).
Among the study population, 14.3% of women received Tdap during pregnancy (Table 1). 
Differences in vaccination coverage by maternal race and ethnicity were noted; 17.6% of 
whites, 8.4% of blacks, 11.9% of Asians, and 21.9% of Native Americans received Tdap 
during pregnancy. Among Hispanic women, 15.3% received Tdap, whereas 6.8% of Arab 
women received the vaccine during pregnancy. Based on bivariate analyses, infant’s 
gestational age (full-term versus pre-term) and maternal age at delivery were significant 
predictors of Tdap vaccination (p≤0.001). Adequacy of prenatal care was not a predictor of 
Tdap vaccination. Women whose care was rated “adequate” or “adequate plus” were not 
more likely to have been vaccinated than women whose care was rated “intermediate” or 
“inadequate.”
Unadjusted and adjusted relative risks (RRs) and 95% confidence intervals (CIs) for Tdap 
vaccination were calculated based on maternal race and ethnicity (Table 2). Whites were 
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significantly more likely to receive Tdap compared with blacks (RR = 2.1; CI = 1.8–2.3), 
Asians (RR = 1.5; CI = 1.1–2.0), and Arabs (RR = 2.6; CI = 1.9–3.7). No significant 
difference in Tdap coverage was observed between white women and Hispanic women (RR 
= 1.1, CI = 1.0–1.4) or between white women and Native American women (RR = 0.8, CI = 
0.5–1.2).
Discussion
Based on Medicaid administrative claims data and the statewide immunization information 
system records, 14.3% of publicly insured women who delivered their first child during 
November 2011–February 2013 received Tdap during pregnancy. Because the 2011 ACIP 
recommendation was only for unvaccinated women and women could have received Tdap 
before pregnancy, a 100% coverage rate for Tdap during pregnancy would not be expected. 
However, based on data from the 2012 National Health Interview Survey, only 14.2% of 
adults reported receiving Tdap in the past 7 years (8). With such a low proportion of the 
general population having received Tdap, a higher proportion of pregnant women in this 
population would be expected to have received Tdap if ACIP recommendations had been 
consistently followed.
Black, Asian, and Arab women were significantly less likely to receive Tdap during 
pregnancy compared with white women, even after controlling for significant predictors of 
vaccination (infant’s gestational age and maternal age at delivery). No significant difference 
in vaccination was observed between Hispanic women or Native American women and 
white women. Racial disparities in prenatal vaccination have also been observed with the 
influenza vaccination; black women (45.4%) were less likely to receive the influenza 
vaccine compared with white women (52.2%) (9).
A previous study examining Tdap coverage among privately insured women of reproductive 
age (regardless of pregnancy status) found that 45.5% of women received Tdap during their 
lifetime (10). No racial or ethnic differences in receipt of Tdap were observed; almost 80% 
of the study population were white women (10). Results based on the privately insured 
population of reproductive age differ from these results for the publicly insured Medicaid 
population, for whom Tdap coverage was assessed during pregnancy.
The findings in this report are subject to at least six limitations. First, only vaccines 
administered during pregnancy were captured in the dataset. This study did not capture pre- 
or post-partum vaccinations because Tdap administrations during those periods are unlikely 
to provide passive immunity to the infant. Second, the Medicaid administrative claims 
database only captures vaccinations that were correctly billed to and paid by Medicaid. 
Third, vaccinations administered at locations other than physicians’ offices might not be 
included in this dataset. Fourth, because birth records were linked to maternal Medicaid 
claims to identify a cohort of women, the study population only included women delivering 
a live infant and cannot represent all pregnant women. Fifth, although no significant 
difference in vaccination was observed between white women and Native American women, 
the result should be interpreted with caution because of small sample sizes. Finally, results 
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from this study are based on a publicly insured population and might not be generalizable to 
other insured populations.
Vaccinating pregnant women remains the best strategy for protecting newborns against 
pertussis. Effective February 2013, ACIP revised its previous recommendation to include a 
Tdap dose during every pregnancy, regardless of previous Tdap vaccination history (6). 
Future studies should reevaluate vaccination coverage to determine whether coverage 
improved after the 2013 ACIP recommendation. Further exploration into reasons for racial 
and ethnic disparities in Tdap vaccination also is needed.
Increased education for clinicians, parents, and families might increase adherence to ACIP 
recommendations. Public health programs should encourage the use of immunization 
registries and immunization prompts, as well as develop better partnerships with clinicians 
responsible for prenatal vaccinations.
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What is already known on this topic?
In 2011, the Advisory Committee on Immunization Practices first recommended routine 
vaccination with tetanus, diphtheria, and acellular pertussis vaccine (Tdap) of pregnant 
women who had never received it. Vaccinating pregnant women is an important strategy 
for providing passive immunity to infants, who are at highest risk from pertussis.
What is added by this report?
To assess whether pregnant women enrolled in Medicaid in Michigan were being 
vaccinated with Tdap during pregnancy, Michigan Medicaid administrative claims data 
and statewide immunization information system data were analyzed. The analysis 
indicated that only 14.3% of women received Tdap during pregnancy, with rates highest 
among non-Hispanic, non-Arab whites and lowest among Arab women. Vaccination was 
related to maternal age and gestational age at birth, but not to adequacy of prenatal care.
What are the implications for public health practice?
Ensuring that all infants receive the protection against pertussis afforded by maternal 
vaccination will require enhanced efforts, such as increased education of clinicians, 
parents, and families.
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TABLE 2
Unadjusted and adjusted relative risks for Tdap vaccination during pregnancy, by maternal race/ethnicity, 
among women aged ≥18 years enrolled in Michigan Medicaid and delivering their first infant during 
November 2011–February 2013
Maternal race/ethnicity
Unadjusted Adjusted
RR (95% CI) RR (95% CI)*
White† versus black† 2.1 (1.9–2.3)§ 2.1 (1.8–2.3)§
White† versus Asian† 1.5 (1.1–2.0)§ 1.5 (1.1–2.0)§
White† versus Native American† 0.8 (0.5–1.2) 0.8 (0.5–1.2)
White† versus Hispanic 1.2 (1.0–1.4) 1.1 (1.0–1.4)
White† versus Arab 2.6 (1.9–3.6)§ 2.6 (1.9–3.7)§
Abbreviations: Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; RR = relative risk; CI = confidence interval.
*Adjusted for maternal age at delivery and gestational age at birth.
†Non-Hispanic and non-Arab.
§Statistically significant.
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